**Background**
Liver fibrosis is a pathological process characterized by the excessive accumulation of extracellular matrix proteins, primarily collagen, in response to chronic liver injury. This condition is often driven by the activation of hepatic stellate cells (HSCs), which transition into myofibroblast-like cells and express markers such as $\alpha$-smooth muscle actin ($\alpha$-SMA) and collagen type I ($\text{Col1A1}$). If left unchecked, liver fibrosis can progress to cirrhosis and hepatocellular carcinoma, making the identification of effective anti-fibrotic agents a critical goal in biomedical research. In this context, we will introduce a potent metabolite with anti-inflammatory and anti-fibrotic properties – Prunasin.
**Definition**
Prunasin is an orally active cyanogenic glucoside and the main metabolite of amygdalin. It serves as a specific inhibitor of rat DNA polymerase $\beta$ with an $\text{IC}_{50}$ value of $98\ \mu\text{M}$.
**In Vitro and In Vivo Studies**
According to the Prunasin description, this compound exhibits significant biological activity in mitigating inflammatory and fibrotic responses. Prunasin in vitro studies demonstrated that concentrations ranging from $6.25$ to $100\ \mu\text{M}$ for $22\text{ h}$ could inhibit the production of nitric oxide (NO) in RAW264.7 cells. Furthermore, in JS1 cells, Prunasin (6.25, 12.5, 25, 50, and $100\ \mu\text{M}$; $22\text{ h}$) significantly suppressed the mRNA expression levels of $\alpha\text{-SMA}$ and $\text{Col1A1}$.
Prunasin In Vivo evaluations were conducted using a mouse model of liver fibrosis induced by carbon tetrachloride ($\text{CCl}_4$). Administration of Prunasin (1.25, 2.5, and $5\text{ mg/kg}$; oral administration; 3 weeks) significantly alleviated morphological abnormalities, including severe inflammatory infiltration, lobular structure disorder, and hepatocyte necrosis. Treatment also led to a significant decrease in serum ALT and AST activities, reduced collagen fiber deposition in liver tissues, and downregulated the expression of $\alpha\text{-SMA}$ and $\text{Col1A1}$. Pharmacokinetic analysis in rats indicated that Prunasin possesses good oral bioavailability ($F = 64.91\%$). For researchers seeking detailed Prunasin technical information, these results highlight its potential as a therapeutic candidate. In conclusion, Prunasin is an orally active cyanogenic glucoside that effectively ameliorates liver injury and fibrosis.
Keywords
Prunasin, 99-18-3, DNA/RNA Synthesis, RAW264.7, JS1, liver fibrosis model, Inhibitor, inhibitor, inhibit
References
[1] Mizushina Y, et al. The cyanogenic glucoside, prunasin (D-mandelonitrile-beta-D-glucoside), is a novel inhibitor of DNA polymerase beta. J Biochem. 1999;126(2):430-436.
[2] Zhang C, et al. Pharmacokinetics and anti-liver fibrosis characteristics of amygdalin: Key role of the deglycosylated metabolite prunasin. Phytomedicine. 2022 May;99:154018.